ReviewDisease markers2019
HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma.
Review in Disease markers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- HMGB1 mediates low-dose ionizing radiation-induced Wnt/β-catenin activation in SRA01/04 cells: Mechanistic clues to early cataractogenesis.International journal of molecular medicine · 2026Article
- Comparative Carcinogenicity of Double-Walled Carbon Nanotubes of Different Lengths Administered by Intratracheal Installation into Rat Lungs.Nanomaterials (Basel, Switzerland) · 2025Article
- HMGB1 as a Key Mediator in Malignant Mesothelioma and a Potential Target for Asbestos-Related Cancer Therapy.Toxics · 2025Article
- Investigating HMGB1 as a potential serum biomarker for early diabetic nephropathy monitoring by quantitative proteomics.iScience · 2024Article
- Tumor-associated neutrophils upregulate PANoptosis to foster an immunosuppressive microenvironment of non-small cell lung cancer.Cancer immunology, immunotherapy : CII · 2023Article
- Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers.Journal of clinical medicine · 2023Review
- Exposure of Rats to Multi-Walled Carbon Nanotubes: Correlation of Inhalation Exposure to Lung Burden, Bronchoalveolar Lavage Fluid Findings, and Lung Morphology.Nanomaterials (Basel, Switzerland) · 2023Review
- [Tumor cell lysate with low content of HMGB1 enhances immune response of dendritic cells against lung cancer in mice].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- ATG5 as biomarker for early detection of malignant mesothelioma.BMC research notes · 2023Article
- Longitudinal monitoring of response to chemotherapy in patients with malignant pleural mesothelioma by biomarkers.Cancer biomarkers : section A of Disease markers · 2023Article
- Assessment of the toxicity and carcinogenicity of double-walled carbon nanotubes in the rat lung after intratracheal instillation: a two-year study.Particle and fibre toxicology · 2022Article
- Use of an antagonist of HMGB1 in mice affected by malignant mesothelioma: a preliminary ultrasound and optical imaging study.European radiology experimental · 2022Article
- Subcellular localization of HMGB1 in human cholangiocarcinoma: correlation with tumor stage.Discover oncology · 2021Article
- The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma.Journal of clinical medicine · 2021Review
- miR-665 is downregulated in glioma and inhibits tumor cell proliferation, migration and invasion by targeting high mobility group box 1.Oncology letters · 2021Article
- Value of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy to treat malignant peritoneal mesothelioma.American journal of translational research · 2021Article
- High mobility group box 1 induces bone pain associated with bone invasion in a mouse model of advanced head and neck cancer.Oncology reports · 2020Article
- High Mobility Group Box 1 in Human Cancer.Cells · 2020Review
- Review
- Cardiopulmonary Bypass Induces Acute Lung Injury via the High-Mobility Group Box 1/Toll-Like Receptor 4 Pathway.Disease markers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant mesothelioma (MM) is a rare, aggressive, and highly lethal cancer that is substantially induced by exposure to asbestos fibers. High-mobility group box 1 (HMGB1) is an intriguing proinflammatory molecule involved in MM. In this review, we describe the possible crucial roles of HMGB1 in carcinogenic mechanisms based on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.